276 related articles for article (PubMed ID: 23754536)
1. Oxymatrine ameliorates non-alcoholic fatty liver disease in rats through peroxisome proliferator-activated receptor-α activation.
Shi L; Shi L; Zhang H; Hu Z; Wang C; Zhang D; Song G
Mol Med Rep; 2013 Aug; 8(2):439-45. PubMed ID: 23754536
[TBL] [Abstract][Full Text] [Related]
2. Oxymatrine attenuates hepatic steatosis in non-alcoholic fatty liver disease rats fed with high fructose diet through inhibition of sterol regulatory element binding transcription factor 1 (Srebf1) and activation of peroxisome proliferator activated receptor alpha (Pparα).
Shi LJ; Shi L; Song GY; Zhang HF; Hu ZJ; Wang C; Zhang DH
Eur J Pharmacol; 2013 Aug; 714(1-3):89-95. PubMed ID: 23791610
[TBL] [Abstract][Full Text] [Related]
3. Beneficial effects of neomangiferin on high fat diet-induced nonalcoholic fatty liver disease in rats.
Zhou C; Zhou J; Han N; Liu Z; Xiao B; Yin J
Int Immunopharmacol; 2015 Mar; 25(1):218-28. PubMed ID: 25661699
[TBL] [Abstract][Full Text] [Related]
4. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
[TBL] [Abstract][Full Text] [Related]
5. [Effects of Electroacupunctrue Combined with Dietary Control on Peroxisome Proliferator-activa- ted Receptor-α, and Liver Fatty Acid-binding Protein Levels in Non-alcoholic Fatty Liver Disease Rats].
Zhang Y; Tang CL; Tian Y; Yuan HZ; Yang H; Tang NZ; Gao RQ; Cao J
Zhen Ci Yan Jiu; 2015 Oct; 40(5):345-51. PubMed ID: 26669188
[TBL] [Abstract][Full Text] [Related]
6. Oxymatrine alleviated hepatic lipid metabolism via regulating miR-182 in non-alcoholic fatty liver disease.
Zhang H; Yang L; Wang Y; Huang W; Li Y; Chen S; Song G; Ren L
Life Sci; 2020 Sep; 257():118090. PubMed ID: 32679144
[TBL] [Abstract][Full Text] [Related]
7. Prevention and treatment effect of total flavonoids in Stellera chamaejasme L. on nonalcoholic fatty liver in rats.
Wang Y; Li JY; Han M; Wang WL; Li YZ
Lipids Health Dis; 2015 Aug; 14():85. PubMed ID: 26242978
[TBL] [Abstract][Full Text] [Related]
8. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D attenuates high fat diet-induced hepatic steatosis in rats by modulating lipid metabolism.
Yin Y; Yu Z; Xia M; Luo X; Lu X; Ling W
Eur J Clin Invest; 2012 Nov; 42(11):1189-96. PubMed ID: 22958216
[TBL] [Abstract][Full Text] [Related]
10. Genistein has beneficial effects on hepatic steatosis in high fat-high sucrose diet-treated rats.
Liu H; Zhong H; Yin Y; Jiang Z
Biomed Pharmacother; 2017 Jul; 91():964-969. PubMed ID: 28514835
[TBL] [Abstract][Full Text] [Related]
11. Osthole improves glucose and lipid metabolism via modulation of PPARα/γ-mediated target gene expression in liver, adipose tissue, and skeletal muscle in fatty liver rats.
Qi ZG; Zhao X; Zhong W; Xie ML
Pharm Biol; 2016; 54(5):882-8. PubMed ID: 26455539
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.
Larter CZ; Yeh MM; Van Rooyen DM; Brooling J; Ghatora K; Farrell GC
J Gastroenterol Hepatol; 2012 Feb; 27(2):341-50. PubMed ID: 21929649
[TBL] [Abstract][Full Text] [Related]
13. [Effect of targeted inhibition of hypoxia-inducible factor-1α by 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole on the progression of non-alcoholic fatty liver disease in rats].
Shen WD; Zhang W; Xu QH; Liu PF
Zhonghua Gan Zang Bing Za Zhi; 2016 Oct; 24(10):749-754. PubMed ID: 27938560
[No Abstract] [Full Text] [Related]
14. Comparison of dietary control and atorvastatin on high fat diet induced hepatic steatosis and hyperlipidemia in rats.
Ji G; Zhao X; Leng L; Liu P; Jiang Z
Lipids Health Dis; 2011 Jan; 10():23. PubMed ID: 21269482
[TBL] [Abstract][Full Text] [Related]
15. Involvement of hepatic peroxisome proliferator-activated receptor α/γ in the therapeutic effect of osthole on high-fat and high-sucrose-induced steatohepatitis in rats.
Zhao X; Xue J; Wang XL; Zhang Y; Deng M; Xie ML
Int Immunopharmacol; 2014 Sep; 22(1):176-81. PubMed ID: 24993341
[TBL] [Abstract][Full Text] [Related]
16. PPARα/γ agonists and antagonists differently affect hepatic lipid metabolism, oxidative stress and inflammatory cytokine production in steatohepatitic rats.
Zhang Y; Cui Y; Wang XL; Shang X; Qi ZG; Xue J; Zhao X; Deng M; Xie ML
Cytokine; 2015 Sep; 75(1):127-35. PubMed ID: 26194065
[TBL] [Abstract][Full Text] [Related]
17. Ascorbic acid inhibits visceral obesity and nonalcoholic fatty liver disease by activating peroxisome proliferator-activated receptor α in high-fat-diet-fed C57BL/6J mice.
Lee H; Ahn J; Shin SS; Yoon M
Int J Obes (Lond); 2019 Aug; 43(8):1620-1630. PubMed ID: 30283077
[TBL] [Abstract][Full Text] [Related]
18. Reduced expression of peroxisome proliferator-activated receptor-alpha may have an important role in the development of non-alcoholic fatty liver disease.
Yeon JE; Choi KM; Baik SH; Kim KO; Lim HJ; Park KH; Kim JY; Park JJ; Kim JS; Bak YT; Byun KS; Lee CH
J Gastroenterol Hepatol; 2004 Jul; 19(7):799-804. PubMed ID: 15209628
[TBL] [Abstract][Full Text] [Related]
19. Li-Gan-Shi-Liu-Ba-Wei-San improves non-alcoholic fatty liver disease through enhancing lipid oxidation and alleviating oxidation stress.
Jiang Y; Chen L; Wang H; Narisi B; Chen B
J Ethnopharmacol; 2015 Dec; 176():499-507. PubMed ID: 26571089
[TBL] [Abstract][Full Text] [Related]
20. Sesamin ameliorates hepatic steatosis and inflammation in rats on a high-fat diet via LXRα and PPARα.
Zhang R; Yu Y; Hu S; Zhang J; Yang H; Han B; Cheng Y; Luo X
Nutr Res; 2016 Sep; 36(9):1022-1030. PubMed ID: 27632923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
